MDXG 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-07-29

• During the second quarter of 2026, we continued to execute our strategic priorities, including expanding our Surgical portfolio, launching new products, advancing recent cost reduction initiatives, and returning capital to shareholders through our Share Repurchase Plan. These efforts contributed to …

• •Net sales were $64 million, a decrease of 35% compared to the prior year period, driven by a 61% decline in Wound sales, partially offset by 15% growth in Surgical sales. Surgical growth was driven by continued adoption of AMNIOFIX®, AMNIOEFFECT®, and our particulate portfolio, as well as contribut…

• •We reported a GAAP net loss of $15 million or $0.10 per diluted share, and ended the quarter with $136 million of cash and cash equivalents.

• •During the quarter, we completed a reduction-in-force and implemented additional cost reduction initiatives designed to align our cost structure with current business needs and support operating efficiency.

• •Separately, we repurchased approximately $13 million of common stock under our Share Repurchase Plan, reflecting our continued commitment to disciplined capital allocation and delivering long-term shareholder value.

相对上期删除的文字 · 来源:10-Q · 2026-04-29

• During the first quarter of 2026, the Company delivered the following financial results:

• •Net sales of $59 million, reflecting a 33% decrease over the prior year period. which was comprised of:

• ◦Surgical net sales of $36 million, reflecting an increase of 13% compared to the prior year period; and

• ◦Wound net sales of $23 million, reflecting a decrease of 60% compared to the prior year period

• •GAAP net loss and net loss margin for the first quarter of 2026 of $11 million and 18%, respectively.